About
Press Release
Printer Friendly Version View printer-friendly version
Back
Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa

EXTON, Pa., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that John Maslowski, President and Chief Executive Officer of Fibrocell, will present at 3:00 pm PDT on Wednesday, October 4 at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California. Mr. Maslowski will discuss the interim results of Fibrocell’s Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa.

A live webcast of Fibrocell’s presentation will be available under the investor relations section of the company’s website at www.fibrocell.com/investors/events, and will also be posted on the Alliance for Regenerative Medicine’s (ARM) website shortly after the event. Please visit Fibrocell’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.    

Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first event of its kind dedicated solely to facilitating connections in this sector, and also a Public Forum lecture.

About Fibrocell

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue.  Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of moderate to severe localized scleroderma.  Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology.  For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.

Trademarks

Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates.  All other names may be trademarks of their respective owners.

Investor Relations Contact:
Karen Casey
484.713.6133
kcasey@fibrocell.com

Primary Logo

Fibrocell Science, Inc.



Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet